Focus on market cap not SP $10.00 means a cap of $370m. If the market for this is the 5 ba ba ba billion claimed in the company presentation than $10.00 will be way short but the 5 ba ba ba billion is the whole market not what ACRX will capture and we are a long way from commercialization at least 1 1/2 years.
$10? I think $6 - $8 with positive ph 3 studies - based on some small cap/micro cap comparison valuations... However, given big short interest, and low float, we are very likely to see massive spike when positive data is reported.
Sound investment advice doesnt come from a YMB This is a speculative play at this point so if your willing to put $20k plus in hopes of a "big" hit your gambling. It may and it may not go to $10.00. The IPO was priced #$%$00 far below original estimates .There were initially 9m shares.There are now over 37m plus options but I can say at least the SP has held up inspite of it. I wouldnt count on such a drastic valuation incresse.
A few catalyst could push ACRX to ten this year. First, 2 more phase three trials due this quarter. If successful, then approval submission to EU and US by mid-year. Positive data from the other Phase 2 trial candidates in 2H. A partner announcement for Europe (which they've said they are aggressively seeking) and EU approval B4 the end of the year would bring in substantial revenue. All very exciting potential catalysts.